NCT03716856: Phase 1 - CAR-BCMA T in Patients With Refractory or Relapsed Multiple - Chinese study
Updated: May 28, 2022
NCT03716856: Phase 1 - Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma
A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR-BCMA T cells in patients with BCMA-positive refractory or relapsed multiple myeloma.
Sponsor
First Affiliated Hospital of Zhejiang University
Collaborator
ClinicalTrials.gov Identifier: NCT03716856
Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma
First Posted : October 23, 2018
Click here for details on Clinicaltrials.gov
Genetic: CAR-BCMA T cells
Drug: Fludarabine
Drug: Cyclophosphamide
703.Adoptive Immunotherapy: Mechanisms and New Approaches| November 13, 2019
Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
Location
China, Zhejiang
China, ZhejiangFirst Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China, 310006,